Results 1 to 10 of about 1,185 (135)

Substandard and Falsified Medicines in Myanmar [PDF]

Pharmacy (Basel, Switzerland), 2020
Background: substandard and falsified medicines (SFMs) are a threat to public health. The availability of SFMs in Myanmar was reported by the World Health Organization (WHO) in 1999, but there have been few systematic surveys on falsified medicines in ...
Naoko Yoshida, Tsuyoshi Tanimoto, Mohammad Sofiqur Rahman   +2 more
exaly   +7 more sources

The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance [PDF]

Nature Communications, 2023
Approximately 10% of antimicrobials used by humans in low- and middle-income countries are estimated to be substandard or falsified. In addition to their negative impact on morbidity and mortality, they may also be important drivers of antimicrobial ...
Sean Cavany, Stella Nanyonga, Cathrin Hauk, Cherry Lim, Joel Tarning, Benn Sartorius, Christiane Dolecek, Céline Caillet, Paul N. Newton, Ben S. Cooper   +9 more
doaj   +7 more sources

The hidden peril: Ecuador's struggle with substandard and falsified medicines [PDF]

Frontiers in Public Health
Juan S Izquierdo-Condoy, Esteban Ortiz-Prado, Jorge Vásconez-González   +2 more
exaly   +6 more sources

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance [PDF]

JMIR Public Health and Surveillance, 2021
The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries.
Elizabeth Pisani, Amalia Hasnida, Mawaddati Rahmi, Maarten Olivier Kok, Steven Harsono, Yusi Anggriani   +5 more
doaj   +5 more sources

Substandard and falsified medicines in Africa: healthcare systems challenges, supply chain issues, regulatory challenges and strategies to increase access to quality medicines [PDF]

Frontiers in Pharmacology
Africa is a unique continent due to high disease burden for both communicable and non-communicable diseases, attracting large-scale distribution of medicines to tackle public health issues.
Sangeeta Tanna, Tarsem Sahota, Irina Ermolina   +2 more
exaly   +4 more sources

Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications [PDF]

Frontiers in Public Health, 2021
Objectives: The objective of this study was to determine the identification rate of substandard and falsified medications and its association with knowledge among public.Methods: This descriptive cross-sectional study was conducted in different ...
Faris El-Dahiyat, Khairi M. S. Fahelelbom, Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari   +3 more
doaj   +5 more sources

Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries [PDF]

Frontiers in Pharmacology, 2018
Substandard and falsified (SF) medicines have emerged as a global public health issue within the last two decades especially in low- and middle-income countries (LMICs). Serious consequences of this problem include a loss of trust and increased financial
Ulrike Holzgrabe
exaly   +4 more sources

Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review [PDF]

Journal of Pharmaceutical Policy and Practice
Background The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through ...
Lubna Merchant, Jean Christophe Rusatira, Saifuddin Ahmed   +2 more
exaly   +4 more sources

Substandard and Falsified Medicines, Regulatory Capacity and Public Health: A Narrative Review With a Focus on Africa. [PDF]

Public Health Chall
Weak medicines regulation in Africa enables the circulation of substandard and falsified medicines, undermining treatment outcomes, accelerating antimicrobial resistance and eroding public trust. This narrative review synthesised 38 studies from 2000 to 2025, highlighting regulatory gaps, public health harms and regional disparities.
Vandy A, Samai NO, Abiri OT, Lahai M, Thomas F, Buffa T, Mansaray S, Turay A, Osborne A.   +8 more
europepmc   +2 more sources

Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab [PDF]

Scientific Reports, 2022
This study evaluates the use of the Global Pharma Health Fund (GPHF) Minilab for medicine quality screening by 16 faith-based drug supply organizations located in 13 low- and middle-income countries. The study period included the year before the COVID-19
Gesa Gnegel, Christine Häfele-Abah, Richard Neci, Difäm-EPN Minilab Network, Lutz Heide   +4 more
doaj   +2 more sources